Home | Welcome to Contract Pharma   
Last Updated Wednesday, November 26 2014
Print RSS Feed

Baxter Expands German Cytotoxic Facility



Published February 19, 2013
Related Searches: Filling formulation Contract Manufacturing Parenteral
Baxter International's BioPharma Solutions business is expanding its facility in Halle, Germany with an additional 1,750 square meters at its cytotoxic fill/finish contract manufacturing facility. The expansion allows the company to support early phase drug formulation through commercial scale-up, product launch and lifecycle management. 
 
The expansion includes the installation of a new commercial filling line with two freeze dryers, as well as a clinical filling line with an additional freeze dryer. Both will be equipped with an automated loading/unloading, capping and inspection infrastructure. The expansion is scheduled for completion in 2015.
 
"Cancer incidence is on the rise and cytotoxic therapies continue to be at the center of oncology treatment programs," said Dr. Burkhard Wichert, vice president of manufacturing for Baxter's BioPharma Solutions business. "Through this expansion in Halle, Baxter will continue to support pharmaceutical companies' efforts to address patient needs worldwide."
 
"We believe in our customers and the patients they serve, which is why we continue to invest in the Halle, Germany facility," said Dr. Wichert. "This expansion and our advanced technologies allow Baxter to stay at the forefront of parenteral cytotoxic manufacturing while increasing the current Halle workforce by approximately 10%."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On